Table 2 Efficacy results of the ALTER0303 trial

OS (months, median [range])

9.46 (8.05–10.45)

6.37 (4.93–7.98)

HR (95% CI, P value)

0.70 (0.55–0.89, P = 0.002)

PFS (months, median [range])

5.37 (4.40–5.63)

1.40 (1.07–1.50)

HR (95% CI)

0.25 (0.19–0.31, P < 0.001)

ORR (CR + PR)

9.18%

0.70%

DCR (CR + PR + SD)

80.95%

37.06%